Primary effusion lymphoma (PEL) is an aggressive non‐Hodgkin B cell lymphoma associated to Kaposi's sarcoma‐associated herpes-virus (KSHV), for which there is not an optimal therapy yet. Indeed, cyclophosphamide, doxorubicin, vincristine, and prednisone chemo-therapy, currently used as first‐line therapy, induces only a partial remission of disease in less than half percent of PEL patients. Bortezomib (BZ) is a proteasome inhibitor mainly used for the treatment of Multiple Myeloma (MM). Here we investigated if Chloroquine supplementation could potentiate the outcome of BZ treatment in vivo, in NSG mouse model.

New insights into the Bortezomib-induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model

D'Orazi, Gabriella;
2024-01-01

Abstract

Primary effusion lymphoma (PEL) is an aggressive non‐Hodgkin B cell lymphoma associated to Kaposi's sarcoma‐associated herpes-virus (KSHV), for which there is not an optimal therapy yet. Indeed, cyclophosphamide, doxorubicin, vincristine, and prednisone chemo-therapy, currently used as first‐line therapy, induces only a partial remission of disease in less than half percent of PEL patients. Bortezomib (BZ) is a proteasome inhibitor mainly used for the treatment of Multiple Myeloma (MM). Here we investigated if Chloroquine supplementation could potentiate the outcome of BZ treatment in vivo, in NSG mouse model.
File in questo prodotto:
File Dimensione Formato  
Hematological Oncology - 2024.pdf

Solo gestori archivio

Descrizione: file finale
Tipologia: PDF editoriale
Dimensione 339.22 kB
Formato Adobe PDF
339.22 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/834733
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact